Melphalan-based autologous transplant in octogenarian multiple myeloma patients

Am J Hematol. 2019 Jan;94(1):E2-E5. doi: 10.1002/ajh.25310. Epub 2018 Oct 31.

Authors

Neeraj Y Saini¹, Romil Patel¹, Ankur Varma¹, Qaiser Bashir¹, Ruby Delgado¹, Gabriela Rondon¹, Uday R Popat¹, Chitra M Hosing¹, Yago Nieto¹, Partow Kebriaei¹, Amin M Alousi¹, Sairah Ahmed², Donna M Weber², Sheeba K Thomas², Hans C Lee², Elisabet E Manasanch², Krina K Patel², Robert Z Orlowski², Richard E Champlin¹, Muzaffar H Qazilbash¹

Affiliations

¹ Department of Stem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston, Texas.
² Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, Texas.

PMID: 30300461
DOI: 10.1002/ajh.25310

No abstract available

Publication types

Letter

MeSH terms

Age Factors
Aged, 80 and over
Antineoplastic Agents, Alkylating / therapeutic use*
Combined Modality Therapy
Female
Hematopoietic Stem Cell Mobilization
Hematopoietic Stem Cell Transplantation*
Humans
Lenalidomide / therapeutic use
Maintenance Chemotherapy
Male
Melphalan / therapeutic use*
Multiple Myeloma / drug therapy
Multiple Myeloma / therapy*
Myeloablative Agonists / therapeutic use*
Remission Induction
Transplantation Conditioning / methods*
Transplantation, Autologous

Substances

Antineoplastic Agents, Alkylating
Myeloablative Agonists
Lenalidomide
Melphalan